SCHEMBL19831569

SCHEMBL19831569

NCCC(O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 20/20 0.70
▸ LYN P07948 3/20 0.68
▸ LCK P06239 2/20 0.68
▸ EGFR P00533 3/20 0.65
▸ TEC P42680 3/20 0.65
▸ BMX P51813 3/20 0.65
▸ TXK P42681 2/20 0.65
▸ FGFR2 P21802 2/20 0.65
▸ ITK Q08881 2/20 0.65
▸ FLT3 P36888 2/20 0.65
▸ BLK P51451 2/20 0.65
▸ RIPK2 O43353 1/20 0.65
▸ NR1I2 O75469 1/20 0.65
▸ SLC22A3 O75751 1/20 0.65
▸ LATS1 O95835 1/20 0.65
▸ NUDT14 O95848 1/20 0.65
▸ ABL1 P00519 1/20 0.65
▸ ERBB2 P04626 1/20 0.65
▸ FYN P06241 1/20 0.65
▸ PGR P06401 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22625403 0.93 BTK (0.71) BTKLYNLCKEGFRTEC
SCHEMBL23223138 0.88 BTK (0.68) BTKLYNLCKEGFRTEC
SCHEMBL18493108 0.88 BTK (0.73) BTKLYNLCKEGFRTEC
SCHEMBL21398244 0.88 BTK (0.73) BTKLYNLCKEGFRTEC
SCHEMBL23409076 0.87 BTK (0.74) BTKLYNLCKEGFRTEC
SCHEMBL24827796 0.87 BTK (0.74) BTKLYNLCKEGFRTEC
SCHEMBL18102571 0.87 BTK (0.69) BTKLYNLCKEGFRTEC
SCHEMBL1613301 0.87 BTK (0.62) BTKLYNLCKEGFRTEC
SCHEMBL30615730 0.86 BTK (0.75) BTKLYNLCKEGFRTEC
SCHEMBL19519589 0.86 BTK (0.71) BTKLYNLCKEGFRTEC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266535-B2 Inhibitor of FLT3 kinase and use thereof HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2019-04-23 — — US disclosed
US-20180030054-A1 NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2018-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030054-A1 NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF FLT3, FLT1, FGFR1 BTK 32/4885LYN 145/4885LCK 114/4885
US-10266535-B2 Inhibitor of FLT3 kinase and use thereof FLT3, FLT1, FGFR1 BTK 35/4885LYN 176/4885LCK 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback